MUC1-specific cytotoxic T lymphocytes in cancer therapy: Induction and challenge

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Roulois, David ^a   Grégoire, Marc ^a   Fonteneau, Jean François ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AS 1402; CANCER VACCINE; EMEPEPIMUT S; HLA ANTIGEN; LETROZOLE; MUCIN 1; T LYMPHOCYTE VACCINE; TG 4010; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADOPTIVE TRANSFER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CELL SPECIFICITY; COLON CANCER; CYTOTOXIC T LYMPHOCYTE; GENE INDUCTION; GENE OVEREXPRESSION; GLYCOSYLATION; HLA TYPING; HUMAN; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; ANIMAL; CLINICAL TRIAL (TOPIC); CYTOLOGY; DISEASE MODEL; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; MOUSE; NEOPLASM; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; MICE; MUCIN-1; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84874606550     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/871936     Document Type: Review

References (83)

1. Dunn G. P., Old L. J., Schreiber R. D., The three Es of cancer immunoediting. Annual Review of Immunology 2004 22 329 360 2-s2.0-2542430341 10.1146/annurev.immunol.22.012703.104803 (Pubitemid 38680426)
2. Traversari C., van der Bruggen P., Luescher I. F., Lurquin C., Chomez P., van Pel A., de Plaen E., Amar-Costesec A., Boon T., A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. Journal of Experimental Medicine 1992 176 5 1453 1457 2-s2.0-0026645959 10.1084/jem.176.5.1453
3. Kessler J. H., Melief C. J. M., Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007 21 9 1859 1874 2-s2.0-34548138945 10.1038/sj.leu.2404787 (Pubitemid 47299958)
4. Müller S., Alving K., Peter-Katalinic J., Zachara N., Gooley A. A., Hanisch F. G., High density O-glycosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. The Journal of Biological Chemistry 1999 274 26 18165 18172 2-s2.0-0033603316 10.1074/jbc.274.26.18165 (Pubitemid 29293800)
5. Kufe D. W., Functional targeting of the MUC1 oncogen in human cancers. Cancer Biology and Therapy 2009 8 13 1197 1203 2-s2.0-68149182606
6. Kufe D., Oncogenic function of the MUC1 receptor subunit in gene regulation. Oncogene 2010 29 42 5663 5666 2-s2.0-77958499974 10.1038/onc.2010.334
7. Gendler S. J., Lancaster C. A., Taylor-Papadimitriou J., Duhig T., Peat N., Burchell J., Pemberton L., Lalani E. N., Wilson D., Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. The Journal of Biological Chemistry 1990 265 25 15286 15293 2-s2.0-0025029968
8. Lan M. S., Batra S. K., Qi W. N., Metzgar R. S., Hollingsworth M. A., Cloning and sequencing of a human pancreatic tumor mucin cDNA. The Journal of Biological Chemistry 1990 265 25 15294 15299 2-s2.0-0025029969
9. Burchell J., Gendler S., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., Lamport D., Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Research 1987 47 20 5476 5482 2-s2.0-0023617395 (Pubitemid 17152966)
10. Girling A., Bartkova J., Burchell J., Gendler S., Gillett C., Taylor-Paradimitriou J., A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. International Journal of Cancer 1989 43 6 1072 1076 2-s2.0-0024353046 (Pubitemid 19158040)
11. Takeuchi H., Kato K., Denda-Nagai K., Hanisch F. G., Clausen H., Irimura T., The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl α 2-3galactosyl β 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat. Journal of Immunological Methods 2002 270 2 199 209 2-s2.0-0037114276 10.1016/S0022- 1759(02)00298-3
12. Lloyd K. O., Burchell J., Kudryashov V., Yin B. W. T., Taylor-Papadimitriou J., Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines: demonstration of simpler and fewer glycan chains in tumor cells. The Journal of Biological Chemistry 1996 271 52 33325 33334 2-s2.0-0030466993 10.1074/jbc.271.52.33325 (Pubitemid 27010142)
13. Springer G. F., T and Tn, general carcinoma autoantigens. Science 1984 224 4654 1198 1206 2-s2.0-0021141716 (Pubitemid 14109457)
14. Barnd D. L., Lan M. S., Metzgar R. S., Finn O. J., Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America 1989 86 18 7159 7163 2-s2.0-0024454148 (Pubitemid 19240884)
15. Ioannides C. G., Fisk B., Jerome K. R., Irimura T., Wharton J. T., Finn O. J., Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. Journal of Immunology 1993 151 7 3693 3703 2-s2.0-0027234878 (Pubitemid 23282681)
16. Takahashi T., Makiguchi Y., Hinoda Y., Kakiuchi H., Nakagawa N., Imai K., Yachi A., Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. Journal of Immunology 1994 153 5 2102 2109 2-s2.0-0027968669 (Pubitemid 24256681)
17. Noto H., Takahashi T., Makiguchi Y., Hayashi T., Hinoda Y., Imai K., Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. International Immunology 1997 9 5 791 798 2-s2.0-0030996555 10.1093/intimm/9.5. 791 (Pubitemid 27226403)
18. Jerome K. R., Barnd D. L., Bendt K. M., Boyer C. M., Taylor-Papadimitriou J., McKenzie I. F. C., Bast R. C., Finn O. J., Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Research 1991 51 11 2908 2916 2-s2.0-0025834851
19. Hinoda Y., Takahashi T., Hayashi T., Suwa T., Makiguchi Y., Itoh F., Adachi M., Imai K., Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells. Journal of Gastroenterology 1998 33 2 164 171 2-s2.0-0031890180 10.1007/s005350050065 (Pubitemid 28143392)
20. Domenech N., Henderson R. A., Finn O. J., Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. Journal of Immunology 1995 155 10 4766 4774 2-s2.0-0028875822
21. Apostolopoulos V., Karanikas V., Haurum J. S., McKenzie I. F. C., Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. Journal of Immunology 1997 159 11 5211 5218 2-s2.0-0031297362 (Pubitemid 127470046)
22. Brossart P., Heinrich K. S., Stuhler G., Behnke L., Reichardt V. L., Stevanovic S., Muhm A., Rammensee H. G., Kanz L., Brugger W., Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999 93 12 4309 4317 2-s2.0-0033564363 (Pubitemid 29279274)
23. Brossart P., Schneider A., Dill P., Schammann T., Grünebach F., Wirths S., Kanz L., Bühring H. J., Brugger W., The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Research 2001 61 18 6846 6850 2-s2.0-0035884392 (Pubitemid 32896509)
24. + T-cells. European Respiratory Journal 2011 38 5 1117 1126
25. Ninkovic T., Kinarsky L., Engelmann K., Pisarev V., Sherman S., Finn O. J., Hanisch F. G., Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Molecular Immunology 2009 47 1 131 140 2-s2.0-68149144929 10.1016/j.molimm.2008.09.032
26. + T cells. Cancer Research 1998 58 22 5066 5070 2-s2.0-0032534067 (Pubitemid 28521162)
27. Hiltbold E. M., Alter M. D., Ciborowski P., Finn O. J., Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cellular Immunology 1999 194 2 143 149 2-s2.0-0033563771 10.1006/cimm.1999.1512 (Pubitemid 29340166)
28. Vlad A. M., Muller S., Cudic M., Paulsen H., Otvos L., Hanisch F. G., Finn O. J., Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. Journal of Experimental Medicine 2002 196 11 1435 1446 2-s2.0-0037011127 10.1084/jem.20020493 (Pubitemid 35424938)
29. Napoletano C., Rughetti A., Agervig Tarp M. P., Coleman J., Bennett E. P., Picco G., Sale P., Denda-Nagai K., Irimura T., Mandel U., Clausen H., Frati L., Taylor-Papadimitriou J., Burchell J., Nuti M., Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Research 2007 67 17 8358 8367 2-s2.0-34548593215 10.1158/0008-5472.CAN-07-1035 (Pubitemid 47395175)
30. Hiltbold E. M., Vlad A. M., Ciborowski P., Watkins S. C., Finn O. J., The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. Journal of Immunology 2000 165 7 3730 3741 2-s2.0-0034292388 (Pubitemid 32057279)
31. Ninkovic T., Hanisch F. G., O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. Journal of Immunology 2007 179 4 2380 2388 2-s2.0-34848868110
32. Peat N., Gendler S. J., Lalani E. N., Duhig T., Taylor-Papadimitriou J., Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Research 1992 52 7 1954 1960 2-s2.0-0026752034
33. Soares M. M., Mehta V., Finn O. J., Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. Journal of Immunology 2001 166 11 6555 6563 2-s2.0-0035339389 (Pubitemid 32467194)
34. Kohlgraf K. G., Gawron A. J., Higashi M., VanLith M. L., Shen X., Caffrey T. C., Anderson J. M., Hollingsworth M. A., Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunology, Immunotherapy 2004 53 12 1068 1084 2-s2.0-8644232489 10.1007/s00262-004-0557-1 (Pubitemid 39506396)
35. Rowse G. J., Tempero R. M., VanLith M. L., Hollingsworth M. A., Gendler S. J., Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Research 1998 58 2 315 321 2-s2.0-0031963862 (Pubitemid 28047073)
36. Tempero R. M., Rowse G. J., Gendler S. J., Hollingsworth M. A., Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. International Journal of Cancer 1999 80 4 595 599 10.1002/(SICI)1097-0215(19990209)80: 4<595::AID-IJC18>3.0.CO;2-B (Pubitemid 29047526)
37. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. Journal of Immunology 1998 161 10 5500 5506 2-s2.0-0032533812 (Pubitemid 28519113)
38. Budiu R. A., Diaconu I., Chrissluis R., Dricu A., Edwards R. P., Vlad A. M., A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Disease Models and Mechanisms 2009 2 11-12 593 603 2-s2.0-70549086639 10.1242/dmm.002535
39. Ryan S. O., Vlad A. M., Islam K., Gariépy J., Finn O. J., Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biological Chemistry 2009 390 7 611 618 2-s2.0-68149166302 10.1515/BC.2009.070
40. Ryan S. O., Turner M. S., Gariépy J., Finn O. J., Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Research 2010 70 14 5788 5796 2-s2.0-77955018971 10.1158/0008-5472.CAN-09-4519
41. Tang C. K., Sheng K. C., Pouniotis D., Esparon S., Son H. Y., Kim C. W., Pietersz G. A., Apostolopoulos V., Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine 2008 26 31 3827 3834 2-s2.0-46149114885 10.1016/j.vaccine.2008.05.008
42. Farkas A. M., Finn O. J., Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Seminars in Immunology 2010 22 3 125 131 2-s2.0-77953621768 10.1016/j.smim.2010.03.003
43. Deguchi T., Tanemura M., Miyoshi E., Nagano H., Machida T., Ohmura Y., Kobayashi S., Marubashi S., Eguchi H., Takeda Y., Ito T., Mori M., Doki Y., Sawa Y., Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express α -Gal epitopes: a novel approach to immunotherapy in pancreatic cancer. Cancer Research 2010 70 13 5259 5269 2-s2.0-77954363486 10.1158/0008-5472.CAN-09-4313
44. Kovjazin R., Volovitz I., Kundel Y., Rosenbaum E., Medalia G., Horn G., Smorodinsky N. I., Brenner B., Carmona L., ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine 2011 29 29-30 4676 4686 2-s2.0-79960644754 10.1016/j.vaccine.2011.04.103
45. Choi D. H., Woo J. K., Choi Y., Seo H. S., Kim C. W., A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene. Molecular Medicine Reports 2011 4 5 885 890 2-s2.0-79960412308 10.3892/mmr.2011.525
46. Chen J., Li H. Y., Wang D., Zhao J. J., Guo X. Z., Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro. Journal of Gastroenterology and Hepatology 2011 26 10 1509 1518 10.1111/j.1440-1746.2011.06778.x
47. Wright S. E., Quinlin I. S., Rewers-Felkins K. A., Dombrowski K. E., Phillips C. A., Retention of immunogenicity produced by mucin1 peptides with glycosylation site substitutions. Immunopharmacology and Immunotoxicology 2010 32 4 647 655 2-s2.0-78149249609 10.3109/08923971003671082
48. Kobukai S., Kremers G. J., Cobb J. G., Baheza R., Xie J., Kuley A., Zhu M., Pham W., Induction of antitumor immunity by dendritic cells loaded with membrane-translocating mucin 1 peptide antigen. Translational Oncology 2011 4 1 1 8 2-s2.0-79251583791 10.1593/tlo.10166
49. Lakshminarayanan V., Thompson P., Wolfert M. A., Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proceedings of the National Academy of Sciences of the United States of America 2012 109 1 261 266 10.1073/pnas. 1115166109
50. Sugiura D., Aida S., Denda-nagai K., Takeda K., Kamata-sakurai M., Yagita H., Irimura T., Differential effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and metastases. Cancer Science 2008 99 12 2477 2484 2-s2.0-57349179030 10.1111/j.1349-7006.2008.00967.x
51. Choi Y., Jeon Y. H., Jang J. Y., Chung J. K., Kim C. W., Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination. Molecular Therapy 2011 19 5 979 989 2-s2.0-79955582731 10.1038/mt.2010.235
52. Jeon Y. H., Choi Y., Kim H. J., Kang J. H., Kim C. W., Jeong J. M., Lee D. S., Chung J. K., In vivo bioluminescence visualization of antitumor effects by human MUCI vaccination. Molecular Imaging 2007 6 5 297 303 2-s2.0-35548975223 10.2310/7290.2007.00027 (Pubitemid 350013535)
53. Trumpfheller C., Longhi M. P., Caskey M., Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. Journal of Internal Medicine 2012 271 2 183 192 10.1111/j.1365-2796.2011.02496.x
54. Rong Y., Jin D., Wu W., Lou W., Wang D., Kuang T., Ni X., Qin X., Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 2009 9, article 191 2-s2.0-67650092642 10.1186/1471-2407-9-191
55. Massé D., Ebstein F., Bougras G., Harb J., Meflah K., Grégoire M., Increased expression of inducible HSP70 in apoptotic cells is correlated with their efficacy for antitumor vaccine therapy. International Journal of Cancer 2004 111 4 575 583 2-s2.0-3843132104 10.1002/ijc.20249 (Pubitemid 39045325)
56. Pinkhasov J., Alvarez M. L., Rigano M. M., Piensook K., Larios D., Pabst M., Grass J., Mukherjee P., Gendler S. J., Walmsley A. M., Mason H. S., Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice. Plant Biotechnology Journal 2011 9 9 991 1001 2-s2.0-79960066708 10.1111/j.1467-7652.2011.00614.x
57. Apostolopoulos V., Pietersz G. A., Tsibanis A., Tsikkinis A., Drakaki H., Loveland B. E., Piddlesden S. J., Plebanski M., Pouniotis D. S., Alexis M. N., McKenzie I. F., Vassilaros S., Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Research 2006 8 3, article R27 2-s2.0-33745126667 10.1186/bcr1505
58. Ramlau R., Quoix E., Rolski J., Pless M., Lena H., Lévy E., Krzakowski M., Hess D., Tartour E., Chenard M. P., Limacher J. M., Bizouarne N., Acres B., Halluard C., Velu T., A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. Journal of Thoracic Oncology 2008 3 7 735 744 2-s2.0-50349090322 10.1097/JTO.0b013e31817c6b4f
59. Dreicer R., Stadler W. M., Ahmann F. R., Whiteside T., Bizouarne N., Acres B., Limacher J. M., Squiban P., Pantuck A., MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Investigational New Drugs 2009 27 4 379 386 2-s2.0-67651173157 10.1007/s10637-008-9187-3
60. Oudard S., Rixe O., Beuselinck B., Linassier C., Banu E., MacHiels J. P., Baudard M., Ringeisen F., Velu T., Lefrere-Belda M. A., Limacher J. M., Fridman W. H., Azizi M., Acres B., Tartour E., A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunology, Immunotherapy 2011 60 2 261 271 2-s2.0-79151471986 10.1007/s00262-010-0935-9
61. Quoix E., Ramlau R., Westeel V., Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. The Lancet Oncology 2011 12 12 1125 1133 10.1016/S1470-2045(11) 70259-5
62. Ohyanagi F., Horai T., Sekine I., Yamamoto N., Nakagawa K., Nishio M., Senger S., Morsli N., Tamura T., Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III nsclc after primary chemoradiotherapy: preliminary results from a phase I/II study. Japanese Journal of Clinical Oncology 2011 41 5 718 722 2-s2.0-79955862560 10.1093/jjco/hyr021 hyr021
63. Butts C., Maksymiuk A., Goss G., Soulières D., Marshall E., Cormier Y., Ellis P. M., Price A., Sawhney R., Beier F., Falk M., Murray N., Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. Journal of Cancer Research and Clinical Oncology 2011 137 9 1337 1342 2-s2.0-79959982541 10.1007/s00432-011-1003-3
64. Wu Y. L., Park K., Soo R. A., INSPIRE: a phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer 2011 11, artcle 430 10.1186/1471-2407-11- 430
65. Butts C., Murray R. N., Smith C., Ellis P., Jasas K., Maksymiuk A., Goss G., Ely G., Beier F., Soulières D., A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clinical Lung Cancer 2010 11 6 391 395 2-s2.0-78649235731 10.3816/CLC.2010.n.101
66. Wright S. E., Rewers-Felkins K. A., Quinlin I. S., Phillips C. A., Townsend M., Philip R., Zorsky P., Klug P., Dai L., Hussain M., Thomas A. A., Sundaramurthy C., Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients-a phase III study tumor burden influences CTL development. Immunological Investigations 2009 38 8 820 838 2-s2.0-70350780494 10.3109/08820130903278089
67. Lepisto A. J., Moser A. J., Zeh H., A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Therapy 2008 6 B 955 964
68. Kondo H., Hazama S., Kawaoka T., Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Research 2008 28 1B 379 387 (Pubitemid 351362841)
69. Dobrzanski M. J., Rewers-Felkins K. A., Samad K. A., Immunotherapy with IL-10- and IFN-gamma-producing CD4 effector cells modulate, "Natural" and "Inducible" CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunology, Immunotherapy 2012 61 6 839 854
70. Mohebtash M., Tsang K. Y., Madan R. A., A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research 2011 17 22 7164 7173 10.1158/1078-0432.CCR-11-0649
71. Ibrahim N. K., Yariz K. O., Bondarenko I., Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clinical Cancer Research 2011 17 21 6822 6830 10.1158/1078-0432.CCR-11-1151
72. Pegram M. D., Borges V. F., Ibrahim N., Fuloria J., Shapiro C., Perez S., Wang K., Schaedli Stark F., Courtenay Luck N., Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Research 2009 11 5, article R73 2-s2.0-77449106552 10.1186/bcr2409
73. + immune responses and induce clinical benefit in vaccinated patients. Molecular Therapy 2011 19 5 990 999 2-s2.0-79955630363 10.1038/mt.2010.289
74. Sharma S., Srivastava M. K., Harris-White M., Lee J. M., Dubinett S., MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Expert Opinion on Biological Therapy 2011 11 8 987 990 2-s2.0-79959882697 10.1517/14712598.2011.598146
75. Sangha R., North S., L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opinion on Biological Therapy 2007 7 11 1723 1730 2-s2.0-36048986266 10.1517/14712598.7.11.1723 (Pubitemid 350157497)
76. Palmer M., Parker J., Modi S., Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clinical Lung Cancer 2001 3 1 49 57 10.3816/CLC.2001.n.018 (Pubitemid 32904315)
77. Kawaoka T., Takashima M., Yamamoto K., Ueno T., Oka M., Adoptive immunotherapy using MUC1-specific CTLs for unresectable pancreatic cancer. Nippon Rinsho 2006 64 supplement 1 279 282
78. Lepisto A. J., Moser A. J., Zeh H., A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Therapy 2008 6 B 955 964
79. Wright S. E., Rewers-Felkins K. A., Quinlin I. S., Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients-a phase I/II study. Immunological Investigations 2009 38 8 820 838
80. Raina D., Ahmad R., Rajabi H., Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. International Journal of Oncology 2012 40 5 1643 1649 10.3892/ijo.2011.1308
81. Raina D., Kosugi M., Ahmad R., Panchamoorthy G., Rajabi H., Alam M., Shimamura T., Shapiro G. I., Supko J., Kharbanda S., Kufe D., Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Molecular Cancer Therapeutics 2011 10 5 806 816 2-s2.0-79955992775 10.1158/1535-7163.MCT-10-1050
82. Brayman M. J., Dharmaraj N., Lagow E., Carson D. D., MUC1 expression is repressed by protein inhibitor of activated signal transducer and activator of transcription-y. Molecular Endocrinology 2007 21 11 2725 2737 2-s2.0-35648951666 10.1210/me.2006-0539 (Pubitemid 350035154)
83. D. Roulois, C. Blanquart, C. Panterne et al., "Downregulation of MUC1 expression and its recognition by CD8+T cells on the surface of malignant pleural mesothelioma cells treated with HDACi," European Journal of Immunology, vol. 42, no. 3, pp. 783-789, 2012.